NGL Fine-Chem Limited

NSE NGLFINE.NS

NGL Fine-Chem Limited EBT Margin for the year ending March 31, 2024: 16.07%

NGL Fine-Chem Limited EBT Margin is 16.07% for the year ending March 31, 2024, a 63.29% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

NGL Fine-Chem Limited EBT Margin for the year ending March 31, 2023 was 9.84%, a -53.78% change year over year.
NGL Fine-Chem Limited EBT Margin for the year ending March 31, 2022 was 21.29%, a -30.03% change year over year.
NGL Fine-Chem Limited EBT Margin for the year ending March 31, 2021 was 30.43%, a 275.43% change year over year.
NGL Fine-Chem Limited EBT Margin for the year ending March 31, 2020 was 8.10%, a -55.67% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NSE: NGLFINE.NS

NGL Fine-Chem Limited

CEO	Mr. Rahul Jayant Nachane
IPO Date	July 8, 2022
Location	India
Headquarters	301, E Square
Employees	682
Sector	Healthcare
Industries Pharmaceuticals Chemicals & Advanced Materials Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care Pet Food Plastics

Description

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin for animal health applications; and nitazoxanide, atovaquone, and ranolazine for human health applications. The company also provides various intermediate products; and finished dosage forms in granules and tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Key trends

Past 5 years